Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.

British journal of haematology - 1 Apr 2015

Wei Andrew, Tan Peter, Perruzza Sarah, Govindaraj Chindu, Fleming Shaun, McManus Julie, Avery Sharon, Patil Sushrut, Stevenson William, Plebanski Magdalena, Spencer Andrew

Abstract excerpt

In this Phase 1b study, the safety and tolerability of maintenance therapy, comprising lenalidomide (0-25 mg, days 5-25) in combination with azacitidine (50-75 mg/m(2) , days 1-5) every 28 d, was explored in 40 patients with acute myeloid leukaemia (AML) in complete remission after chemotherapy. Eligibility included AML in first complete remission (CR1) with adverse risk karyotype (n = 8), fms-related tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA (Cytosine-5-)-Methyltransferases

Share to DNA Methyltransferase 3A

Share to Lenalidomide

Share to Maintenance Chemotherapy

Share to Nucleophosmin

Share to Thalidomide

Source

Identifiers

PMID: 25643589
DOI: 10.1111/bjh.13281

Genes

NPM1
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.PMID 25643589Read ↗

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.Semantic proximity Read ↗

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.Semantic proximity Read ↗

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity Read ↗

Efficacy and Safety of Azacitidine Plus Low-dose Dasatinib Maintenance Therapy for Patients with Intermediate and High-risk Acute Myeloid Leukemia: A Prospective, Randomized, Phase Ⅱ Clinical TrialSemantic proximity Read ↗

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaSemantic proximity Read ↗

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Semantic proximity Read ↗

A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemiaSemantic proximity Read ↗

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity Read ↗

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.Semantic proximity Read ↗

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow.Semantic proximity Read ↗

Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyondSemantic proximity Read ↗

Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.